Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 59

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 59
---
 options, stock appreciation rights, or similar instruments with option-like features. Because the Compensation Committee has a practice of generally granting stock options as described above, the Compensation Committee generally does not take MNPI into account when determining the timing of awards and it does not seek to time the award of stock options in relation to the Company’s public disclosure of MNPI. The Company has not timed the release of MNPI for the purpose of affecting the value of executive compensation.

40

TABLE OF CONTENTS

The following table is being provided pursuant to Item 402(x)(2) of Regulation S-K.

| Name                          |     | Grant Date |     |  Number of 
 Securities 
 Underlying 
      Award |     |     Exercise 
 Price of the 
 Award ($/Sh) |     |    Grant Date 
 Fair Value of 
  the Award(1) |     | Percentage change in the closing        
 market price of the securities          
 underlying the award between the        
 trading day ending immediately prior    
 to the disclosure of material nonpublic 
 information and the trading day         
 beginning immediately following the     
 disclosure of material nonpublic        
 information                             |
| Marshall Fordyce, M.D., Ph.D. |     | —          |     |          — |     |            — |     |             — |     | —                                       |
| Jason Carter                  |     | —          |     |          — |     |            — |     |             — |     | —                                       |
| Robert Brenner, M.D.          |     | 01/03/2024 |     |    350,000 |     |        15.36 |     |     3,627,050 |     | 24%                                     |

| (1) | The amounts disclosed represent the aggregate grant date fair value of the option awards granted to our named executive officers during fiscal years 2023 and 2024 under our 2021 Plan, computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 8 to our audited financial statements included within our Annual Report on Form 10-K for the year ended December 31, 2024. This amount does not reflect the actual economic value that may be realized by the named executive officer. |

| (2) | Dr. Brenner was granted an option to purchase 350,000 shares of our Class A common stock on January 3, 2024, his first date of employment